An EGFR Pathway-Oriented Pharmacogenetic Study in MetastaticColorectal Cancer Patients Receiving Panitumumab and Irinotecan

We tested the predictive value of gene polymorphisms potentially linked to the pharmacodynamics of panitumumab and irinotecan.

[1]  J. Douillard,et al.  Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer , 2016, Current medical research and opinion.

[2]  H. McLeod,et al.  Clinical implementation of pharmacogenetics , 2016, Drug metabolism and personalized therapy.

[3]  Hua-Fu Zhou,et al.  Association of epidermal growth factor receptor (EGFR) gene polymorphism with lung cancer risk: a systematic review , 2014, Journal of receptor and signal transduction research.

[4]  H. Lenz,et al.  The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy , 2013, The Pharmacogenomics Journal.

[5]  Xiang Liu,et al.  Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians , 2013, The Pharmacogenomics Journal.

[6]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[7]  Carlota Costa,et al.  KRAS mutations in lung cancer. , 2013, Clinical lung cancer.

[8]  C. Tournigand,et al.  Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Ingelman-Sundberg,et al.  Epigenomics and Interindividual Differences in Drug Response , 2012, Clinical pharmacology and therapeutics.

[10]  K. Søreide,et al.  EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. , 2012, Discovery medicine.

[11]  Ping Yang,et al.  Cyclin D1 (CCND1) G870A gene polymorphism is an ethnicity-dependent risk factor for digestive tract cancers: a meta-analysis comprising 20,271 subjects. , 2012, Cancer epidemiology.

[12]  Jing Yang,et al.  CCND1 G870A polymorphism is associated with increased risk of colorectal cancer, especially for sporadic colorectal cancer and in Caucasians: a meta-analysis. , 2012, Clinics and research in hepatology and gastroenterology.

[13]  C. Tournigand,et al.  Therapeutic strategy in unresectable metastatic colorectal cancer , 2012, Therapeutic advances in medical oncology.

[14]  J. Gaudart,et al.  Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer , 2011, BMC Cancer.

[15]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[16]  Wei Zhang,et al.  Exploring the relationship between polymorphic (TG/CA)n repeats in intron 1 regions and gene expression , 2009, Human Genomics.

[17]  F.A.M. Bordonaba,et al.  Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .

[18]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[19]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Dongsheng Tu,et al.  Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.

[21]  Joseph G Ibrahim,et al.  UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. , 2007, Journal of the National Cancer Institute.

[22]  B. Brandt,et al.  Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response , 2006, Clinical Cancer Research.

[23]  Y. Toiyama,et al.  Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report. , 2006, Oncology reports.

[24]  Z. Hua.  Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .

[25]  N. Magné,et al.  Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  K. Zänker,et al.  Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1* , 1999, The Journal of Biological Chemistry.

[27]  N Thatcher,et al.  Alternate splicing produces a novel cyclin D1 transcript. , 1995, Oncogene.